Basic Research and Clinical Treatment of Endometrial Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 6038
Special Issue Editor
Interests: gynecologic oncology; gynecologic surgery; laparoscopy; robotic surgery; cytoreductive surgery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent years, several new insights have emerged regarding the molecular aspects and pathological pathways in endometrial cancer. The application of Next Generation Sequencing technology has revolutionized the traditional classification of Type I and Type II endometrial cancer, and additional molecular risk factors beyond the conventional pathological criteria have been introduced. The assessment of p53 and POLE mutational status has become pivotal in defining patient prognosis, while microsatellite instability primarily holds therapeutic implications. The integration of this perspective into clinical practice has led to the incorporation of molecular classification into the updated FIGO staging system for endometrial cancer in 2023. Furthermore, the exploration of other markers such as beta-catenin and deficiencies in the homologous recombination system is currently underway in endometrial cancer research. Immunohistochemistry has played a critical role in determining the clinical application of these novel prognostic markers. In addition, the mounting evidence regarding the pathological mechanisms in endometrial cancer has led to the identification of numerous potential targets for therapeutic agents.
Concerning risk assessment before surgery, there have been reports of utilizing artificial intelligence in radiology, specifically through radiomics, for predicting outcomes in endometrial cancer. However, current evidence in this area is limited.
Regarding advancements in perioperative care, the Enhanced Recovery After Surgery (ERAS) guidelines have offered evidence-based recommendations aimed at improving clinical outcomes. In summary, substantial progress and ongoing developments hold the promise of enhanced treatment personalization and perioperative care in endometrial cancer patients.
We cordially invite submissions from experts in the field, especially those focusing on the molecular aspects of endometrial cancer and their relevance to therapeutic strategies, impact of radiomics application in endometrial cancer management, and experience with ERAS protocol application in their clinical practice.
Sincerely,
Dr. Roberto Berretta
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- endometrial cancer
- target therapy
- molecular markers
- personalized medicine
- immunoistochemistry
- next generation sequencing
- radiomics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
